Genpact (G) Competitors $45.37 -0.09 (-0.20%) Closing price 03:59 PM EasternExtended Trading$45.36 -0.01 (-0.02%) As of 04:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock G vs. CCRN, BR, GPN, JKHY, EXLS, WEX, EEFT, MMS, PAY, and WUShould you be buying Genpact stock or one of its competitors? The main competitors of Genpact include Cross Country Healthcare (CCRN), Broadridge Financial Solutions (BR), Global Payments (GPN), Jack Henry & Associates (JKHY), ExlService (EXLS), WEX (WEX), Euronet Worldwide (EEFT), Maximus (MMS), Paymentus (PAY), and Western Union (WU). Genpact vs. Its Competitors Cross Country Healthcare Broadridge Financial Solutions Global Payments Jack Henry & Associates ExlService WEX Euronet Worldwide Maximus Paymentus Western Union Cross Country Healthcare (NASDAQ:CCRN) and Genpact (NYSE:G) are related companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, risk, valuation, earnings, dividends, institutional ownership, profitability and analyst recommendations. Do analysts recommend CCRN or G? Cross Country Healthcare currently has a consensus target price of $17.93, suggesting a potential upside of 40.30%. Genpact has a consensus target price of $49.75, suggesting a potential upside of 9.65%. Given Cross Country Healthcare's higher probable upside, research analysts clearly believe Cross Country Healthcare is more favorable than Genpact.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cross Country Healthcare 0 Sell rating(s) 6 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00Genpact 0 Sell rating(s) 5 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.38 Which has better earnings and valuation, CCRN or G? Genpact has higher revenue and earnings than Cross Country Healthcare. Cross Country Healthcare is trading at a lower price-to-earnings ratio than Genpact, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCross Country Healthcare$1.34B0.31-$14.56M-$0.53-24.11Genpact$4.77B1.66$513.67M$2.9315.48 Does the media refer more to CCRN or G? In the previous week, Genpact had 6 more articles in the media than Cross Country Healthcare. MarketBeat recorded 7 mentions for Genpact and 1 mentions for Cross Country Healthcare. Genpact's average media sentiment score of 0.76 beat Cross Country Healthcare's score of 0.31 indicating that Genpact is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cross Country Healthcare 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Genpact 4 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do insiders & institutionals have more ownership in CCRN or G? 96.0% of Cross Country Healthcare shares are owned by institutional investors. Comparatively, 96.0% of Genpact shares are owned by institutional investors. 4.9% of Cross Country Healthcare shares are owned by insiders. Comparatively, 3.1% of Genpact shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. Which has more volatility and risk, CCRN or G? Cross Country Healthcare has a beta of 0.36, meaning that its stock price is 64% less volatile than the S&P 500. Comparatively, Genpact has a beta of 0.94, meaning that its stock price is 6% less volatile than the S&P 500. Is CCRN or G more profitable? Genpact has a net margin of 10.88% compared to Cross Country Healthcare's net margin of -1.41%. Genpact's return on equity of 22.35% beat Cross Country Healthcare's return on equity.Company Net Margins Return on Equity Return on Assets Cross Country Healthcare-1.41% 2.56% 1.84% Genpact 10.88%22.35%10.50% SummaryGenpact beats Cross Country Healthcare on 13 of the 15 factors compared between the two stocks. Get Genpact News Delivered to You Automatically Sign up to receive the latest news and ratings for G and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding G and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart G vs. The Competition Export to ExcelMetricGenpactIT Services IndustryComputer SectorNYSE ExchangeMarket Cap$7.95B$16.53B$28.69B$20.85BDividend Yield1.50%1.50%3.07%3.65%P/E Ratio15.4836.6243.9226.34Price / Sales1.6613.401,807.2659.22Price / Cash12.6325.2638.0622.29Price / Book3.355.117.634.66Net Income$513.67M$434.10M$779.03M$994.58M7 Day Performance2.42%5.03%2.35%-0.29%1 Month Performance7.84%6.76%7.48%4.91%1 Year Performance34.71%21.26%52,761.55%10.53% Genpact Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GGenpact3.1516 of 5 stars$45.37-0.2%$49.75+9.7%+33.7%$7.95B$4.77B15.48140,000Analyst ForecastCCRNCross Country Healthcare3.6127 of 5 stars$12.08+0.1%$17.93+48.4%-18.6%$396.02M$1.26B-22.798,205News CoverageBRBroadridge Financial Solutions4.2981 of 5 stars$236.01+0.4%$250.83+6.3%+14.1%$27.72B$6.51B35.4914,600Positive NewsGPNGlobal Payments4.9925 of 5 stars$79.52+0.9%$111.36+40.1%-19.8%$19.39B$10.11B12.8327,000Trending NewsAnalyst ForecastAnalyst RevisionJKHYJack Henry & Associates3.8091 of 5 stars$176.17+0.6%$185.11+5.1%+5.5%$12.83B$2.22B30.017,170Positive NewsEXLSExlService4.7606 of 5 stars$43.03+1.7%$51.50+19.7%+23.4%$7.00B$1.84B32.6059,500Positive NewsWEXWEX4.8182 of 5 stars$151.60+0.6%$176.90+16.7%-18.9%$5.19B$2.61B19.546,500Upcoming EarningsAnalyst ForecastEEFTEuronet Worldwide4.6376 of 5 stars$102.73+0.0%$126.86+23.5%-6.0%$4.44B$3.99B15.2210,600MMSMaximus3.779 of 5 stars$72.40+1.3%$90.00+24.3%-21.8%$4.08B$5.40B14.3941,100Positive NewsPAYPaymentus4.1634 of 5 stars$30.10+6.0%$36.80+22.2%+45.7%$3.77B$871.74M77.191,307High Trading VolumeWUWestern Union4.9237 of 5 stars$8.32-0.4%$10.78+29.6%-37.1%$2.75B$4.14B3.109,100Analyst Forecast Related Companies and Tools Related Companies Cross Country Healthcare Competitors Broadridge Financial Solutions Competitors Global Payments Competitors Jack Henry & Associates Competitors ExlService Competitors WEX Competitors Euronet Worldwide Competitors Maximus Competitors Paymentus Competitors Western Union Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:G) was last updated on 7/18/2025 by MarketBeat.com Staff From Our PartnersUtah’s New Oil FindThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | Sponsored[ATTENTION] This Crypto Rocket Is About Launch…Every crypto bull market ends with a final surge — the window where fortunes are made fast. According to tw...Crypto Swap Profits | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredTrump's 2025 Economic Revolution Is Here Are Your Retirement Savings Ready?Time is short. Trump's reforms may be coming fast—and the financial system roller coaster may be a ride that y...GoldCo Precious Metals | SponsoredAI Meltdown Imminent: Dump These Stocks Now!If you have any money in the markets, especially in AI stocks… Please click here to see Elon Musk’s new inv...Paradigm Press | SponsoredHedge fund legend humiliates Bitcoin tradersLarry Benedict made $274 million trading on Wall Street… Barron’s ranked his hedge fund in the top 1% world...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Genpact Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Genpact With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
